Pages that link to "Q37315305"
Jump to navigation
Jump to search
The following pages link to Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis (Q37315305):
Displaying 50 items.
- Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders (Q22330767) (← links)
- Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine (Q26783472) (← links)
- Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented at accountability for reasonableness (Q27324818) (← links)
- Developing and evaluating polygenic risk prediction models for stratified disease prevention (Q30251440) (← links)
- Decision making about cancer screening: an assessment of the state of the science and a suggested research agenda from the ASPO Behavioral Oncology and Cancer Communication Special Interest Group (Q33605457) (← links)
- Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group (Q34175545) (← links)
- Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes (Q34243496) (← links)
- Eliciting preferences for priority setting in genetic testing: a pilot study comparing best-worst scaling and discrete-choice experiments (Q34332744) (← links)
- Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). (Q35029538) (← links)
- Willingness to pay for genetic testing for inherited retinal disease (Q35079939) (← links)
- Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis (Q35185164) (← links)
- Points to consider in assessing and appraising predictive genetic tests (Q35263641) (← links)
- Concepts of 'personalization' in personalized medicine: implications for economic evaluation. (Q35575935) (← links)
- Clinical utility of chromosomal microarray analysis in invasive prenatal diagnosis (Q35751507) (← links)
- Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening (Q35822142) (← links)
- A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice (Q35854145) (← links)
- Secondary findings and carrier test frequencies in a large multiethnic sample (Q35865955) (← links)
- Would you test for 5000 Shillings? HIV risk and willingness to accept HIV testing in Tanzania (Q35967841) (← links)
- Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. (Q36136786) (← links)
- Personal utility and genomic information: look before you leap (Q36158668) (← links)
- Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer's Disease (Q36272443) (← links)
- Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis (Q36390515) (← links)
- The Role of Information Provision in Economic Evaluations of Newborn Bloodspot Screening: A Systematic Review (Q36573343) (← links)
- Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most? (Q37397621) (← links)
- Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment (Q37410709) (← links)
- Challenges of translating genetic tests into clinical and public health practice (Q37511706) (← links)
- Issues surrounding the health economic evaluation of genomic technologies (Q37541151) (← links)
- Evaluation of the Validity and Utility of Genetic Testing for Rare Diseases (Q37786243) (← links)
- Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies? (Q38354845) (← links)
- HEADROOM BEYOND THE QUALITY- ADJUSTED LIFE-YEAR: THE CASE OF COMPLEX PEDIATRIC NEUROLOGY. (Q38677769) (← links)
- Personal utility in genomic testing: a systematic literature review. (Q38745230) (← links)
- Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. (Q39352133) (← links)
- Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents (Q39660783) (← links)
- Barriers to integrating personalized medicine into clinical practice: a best-worst scaling choice experiment (Q39664940) (← links)
- First trimester screening cut-offs for noninvasive prenatal testing as a contingent screen: Balancing detection and screen-positive rates for trisomy 21. (Q40125094) (← links)
- Personalized medicine and comparative effectiveness research in an era of fixed budgets (Q42250319) (← links)
- Cost savings through molecular diagnosis for hereditary hemorrhagic telangiectasia (Q45130977) (← links)
- Early-Life Epilepsies and the Emerging Role of Genetic Testing. (Q45947607) (← links)
- A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics (Q46321924) (← links)
- Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. (Q46492914) (← links)
- Valuing the economic benefits of complex interventions: when maximising health is not sufficient (Q46601983) (← links)
- Evaluating the utility of personal genomic information (Q47593006) (← links)
- Diagnosis of rare diseases under focus: impacts for Canadian patients. (Q47771558) (← links)
- Communication strategies for enhancing understanding of the behavioral implications of genetic and biomarker tests for disease risk: the role of coherence (Q48128223) (← links)
- Health utility elicitation: is there still a role for direct methods? (Q48515111) (← links)
- Evaluating the Outcomes Associated with Genomic Sequencing: A Roadmap for Future Research (Q57030713) (← links)
- Valuing the benefits of genetic testing for retinitis pigmentosa: a pilot application of the contingent valuation method (Q57206612) (← links)
- Probleme und Methoden der Gesundheitsökonomie: Personalisierte Medizin als Sonderfall? (Q57697423) (← links)
- Value of genetic testing in the prevention of coronary heart disease events (Q61817425) (← links)
- Cost-Effectiveness Analysis of Diagnosis of Duchenne/Becker Muscular Dystrophy in Colombia (Q88028317) (← links)